SkQ Eye Drop Formulation for Schirmer-Selected Dry Eye
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease often fail to target the underlying causes, relying on temporary relief with artificial tears that may irritate the eyes and do not address long-term symptoms or signs effectively.
Innovation Solution
Population-specific formulations containing mitochondrially-targeted antioxidants (SkQ) are administered topically at concentrations of ≥0.5 μg/mL to treat dry eye disease, focusing on populations with tear production of ≥7 mm measured by a Schirmer's test, improving visual acuity and corneal health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If artificial tears are used to relieve dry eye symptoms, then short-term comfort is improved, but long-term effectiveness deteriorates and eye irritation increases
Solution Approach 1:
The patent converts the harmful effect of oxidative stress that causes dry eye disease into a beneficial treatment by using antioxidants (vitamin C, vitamin E, ferulic acid) to neutralize free radicals and reduce oxidative damage. This transforms the underlying pathological mechanism into a therapeutic approach that addresses the root cause rather than just masking symptoms
Solution Approach 2:
The patent introduces antioxidant compounds as intermediary substances that mediate between the harmful oxidative stress and the ocular tissues. These antioxidants act as mediators that scavenge free radicals, reduce inflammation, and protect cellular structures from damage, thereby providing sustained relief without the irritation caused by artificial tears
2Object-affected harmful factors
If anti-inflammatory and immuno-suppressive drugs are prescribed to reduce inflammation, then inflammation is suppressed, but side effects increase and underlying causes remain unaddressed
Solution Approach 1:
The patent converts the harmful inflammatory process into a beneficial outcome by using antioxidants to address the root cause of inflammation (oxidative stress). Instead of suppressing inflammation with drugs that cause side effects, the treatment neutralizes the free radicals that trigger inflammatory cascades, thereby reducing inflammation naturally without immunosuppression
Solution Approach 2:
The patent enables the eye's own defense mechanisms to work effectively by providing antioxidants that enhance the ocular surface's natural ability to combat oxidative stress. The treatment empowers the body's intrinsic protective systems rather than relying on external immunosuppressive agents, allowing self-regulation of inflammation without drug-induced side effects
3Reliability
If mitochondrially targeted antioxidants are administered at high concentrations, then therapeutic effectiveness is improved, but formulation stability and safety challenges increase
Solution Approach 1:
The patent optimizes the concentration parameters of antioxidant compounds in the formulation to achieve therapeutic effectiveness while maintaining safety. By carefully controlling the amounts of vitamin C, vitamin E, and ferulic acid, and using population-specific formulations based on Schirmer's test results, the patent achieves high efficacy without excessive formulation complexity or safety concerns
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations significantly improve visual acuity and heal central corneal damage in subjects with baseline tear production of ≥7 mm, reducing corneal staining and ocular discomfort, while being safe and effective over a period of administration.
Implementation Method 1
The active drug substance in these studies is an SkQ type mitochondrially targeted antioxidant
Data Source
AI summary
Formulations and methods of using mitochondrially targeted antioxidants (SkQ) to improve dry eye conditions in subjects having a tear production of ≥7 mm measured by a Schirmer's test are provided. The methods provide benefits to the population-specific group of subjects but do not provide benefits to subjects having a tear production of <7 mm, as measured by a Schirmer's test.